The official publication of Turkish Society of Clinical Biochemistry
Objective: Atherosclerotic cardiovascular disease is the leading cause of the increased morbidity and mortality observed in uremic patients. The prevalance of cardiovascular diseases is high in the dialysis patients. Thrombosis is an important contributor to the evolution of...
Objective: Serum paraoxonase (PON1) is a HDL associated esterase and inhibits LDL oxidation. The oxidative modification of LDL plays an important role in the pathogenesis of atherosclerosis. In hemodialysis patients, the increased oxidative stress induces oxidative...
Objective: In this study in which the purpose was to investigate the effect of hemodialysis treatment on cardiac markers and trace elements, serum copper, zinc, homocysteine and lipoprotein (a) levels and ceruloplasmin oxidase and adenosine deaminase activities and compared...
Background: Bromcresol green (BCG) and Bromcresol Purple (BCP) which are dye-binding based methods are widely used in serum albumin analysis in clinical laboratories for many years. It was suggested that discrepancies exist between these methods and these discrepancies are...
Background: Beta-human chorionic gonadotropin (beta-hCG) is secreted in small amounts by all cells and since the hormone is largely excreted by the kidneys, its levels can be elevated in non-pregnantdialysis patients.
Case presentation: A 27-year-old...
Purpose: Although most studies showed that the increase of cardiac biomarkers due to myocardial injury during coronavirus disease (COVID-19) is a strong predictor of adverse clinical events, few studies compared other causes of myocardial injury and COVID-19. In our study,...
Purpose: End-stage renal disease; is a disease characterized by loss of renal function where inflammation is involved in its pathogenesis. Adiponectin is an anti-inflammatory protein secreted from the adipose tissue. ICAM-1 and VCAM-1 are vascular adhesion molecules that...
Fully Diamond OA with no APCs and no submission fees. Your research is freely available to readers worldwide from the day it publishes.
Double-blind peer review from an active editorial team returns a first decision in about 30 days, keeping your manuscript moving.
Backed by the Turkish Society of Clinical Biochemistry, JTCB welcomes submissions from researchers worldwide and reaches an international laboratory audience.
Method validation, analyzer comparisons, reference intervals, quality indicators, preanalytical studies, and instructive clinical case reports.
All manuscripts publish in English and follow ICMJE and COPE guidelines, with Crossref DOIs and TR Dizin indexing ensuring global discoverability.